Quality of life in ovarian cancer.
While there has not been a dramatic improvement in the cure rate of ovarian cancer, >40% of women survive longer than 5 years, with what is commonly considered a "chronic" cancer. In each phase of the illness (diagnosis, surgery and chemotherapy with curative intent, remission and survivorship, relapse and sequential chemotherapy, bowel obstruction and end of life), quality of life (QOL) is one of the most important considerations. There has recently been a large increase in studies reporting the assessment of QOL; that has changed the field from descriptive reporting to quantitative science. There are well-validated, standardized scales, and approximately 10% of randomized cancer trials include health-related QOL as one of the main end points. This article reviews the history and development of QOL evaluation and the 2 main approaches to QOL assessment (psychometric based and utility based) and describes strategies for meaningful interpretation of QOL profiles. While the humanities perhaps teach us much about the value of QOL, the science of the study of QOL will be the foundation and confirmation of many of the anticipated advances for patients.
Penson
Richard
R
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. rpenson@partners.org
Cella
David
D
Wenzel
Lari
L
D017028:Caregivers / Q000523:psychology; D005190:Family / Q000523:psychology; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D010051:Ovarian Neoplasms / Q000523:psychology*; D011594:Psychometrics; D011788:Quality of Life; D019057:Quality-Adjusted Life Years